Nasdaq Ipha News Today

Innate Pharma S.A. (NASDAQ:IPHA – Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 81,300 shares, a growth of 5.7% from the March 31st total of 76,900 shares. Based on an average daily volume of 10,400 shares, […]

Innate Pharma S.A. (NASDAQ:IPHA – Get Free Report) was the recipient of a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 76,700 shares, a drop of 8.9% from the December 31st total of 84,200 shares. Based on an average daily volume of 20,700 shares, […]

Innate Pharma (NASDAQ:IPHA – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Institutional & Insider Ownership 0.3% of Innate […]

HC Wainwright reiterated their buy rating on shares of Innate Pharma (NASDAQ:IPHA – Free Report) in a research report report published on Monday, Benzinga reports. They currently have a $11.50 price target on the stock. Separately, Citigroup reduced their target price on shares of Innate Pharma from $12.00 to $8.00 in a report on Monday. […]

Innate Pharma (NASDAQ:IPHA – Get Rating) and Voyager Therapeutics (NASDAQ:VYGR – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a summary of recent ratings […]

Innate Pharma (NASDAQ:IPHA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The […]

Innate Pharma (NASDAQ:IPHA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The […]

Innate Pharma S.A. (NASDAQ:IPHA – Get Rating) – Stock analysts at SVB Leerink dropped their FY2026 earnings estimates for shares of Innate Pharma in a research report issued on Tuesday, May 10th. SVB Leerink analyst D. Graybosch now anticipates that the company will earn $0.58 per share for the year, down from their previous forecast […]

Innate Pharma (NASDAQ:IPHA – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company’s commercial-stage […]

Innate Pharma S.A. (NASDAQ:IPHA – Get Rating) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 134,700 shares, a growth of 105.0% from the March 15th total of 65,700 shares. Based on an average daily volume of 25,400 shares, the days-to-cover ratio is […]